Confounder factors masking a Leydig-cell ovarian tumor in a post-menopausal woman treated for androgen-positive receptor breast cancer
- 26 April 2017
- journal article
- case report
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 32 (9) , 1-5
Abstract
Post-menopause hyperandrogenism is a condition that needs careful evaluation. Aromatase inhibitors (AI), which are important in the management of positive estrogen breast cancer, and chronic kidney disease (CKD) can puzzle the evaluation of this condition. A postmenopause female with type-2 diabetes and advanced CKD was attended due to progressive virilization, which has started after the introduction of an AI for breast cancer 5 years earlier. Clinical and radiological investigation has confirmed a pure Leydig cell tumor as source of hyperandrogenism. Re-evaluation of the breast tumor immunohistochemistry has shown positive androgen receptor expression and negative expression for estrogen, progesterone and HER-2 receptors. Even though an ovarian tumor was the source of androgen excess, we discuss that AI could exert a slight contribution to patient's virilization by reducing estradiol counterbalance. Also, although the onset of hyperandrogenic symptoms was unclear, we could not exclude that the ovarian tumor had produced enough androgens to play a role in breast tumor progression. This case report supports the literature regarding the possible association between Leydig cell tumor and androgen-receptor-positive breast cancer development. Finally, progressive hyperandrogenic symptoms in postmenopause, even under AI therapy or the presence of advanced CKD, impose a more detailed investigation.Keywords
This publication has 23 references indexed in Scilit:
- Aromatase inhibitor therapy and hair loss among breast cancer survivorsBreast Cancer Research and Treatment, 2013
- Occult leydig cell tumour and androgen-receptor positive breast cancer in a woman with severe hyperandrogenismJournal of Ovarian Research, 2013
- Chapter 1: Definition and classification of CKDKidney International Supplements, 2013
- How should postmenopausal androgen excess be evaluated?Clinical Endocrinology, 2011
- Pure leydig cell tumour of the ovary in a post-menopausal patient with severe hyperandrogenism and erythrocytosisGynecological Endocrinology, 2010
- Extremes of Endogenous Testosterone Are Associated with Increased Risk of Incident Coronary Events in Older WomenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Systemic anticancer therapy in gynecological cancer patients with renal dysfunctionInternational Journal of Gynecological Cancer, 2007
- The hypothalamic-pituitary axis in men and women with chronic kidney diseaseAdvances in Chronic Kidney Disease, 2004
- Reproductive Endocrinology and Pregnancy in Women on HemodialysisSeminars in Dialysis, 1993